AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02737046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
Study NCT03135392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Breast Reconstruction
Description: Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
Study NCT03135392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurotization
Description: Nerve will be reconstructed during autologous breast tissue reconstruction
Study NCT04785612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF
Description: A single dose of 120 mcg RSVpreF for intramuscular injection
Study NCT04785612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single Placebo dose for intramuscular injection to match experimental vaccine
Study NCT00659295 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
Study NCT02456584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA 150
Description: injectable contraceptive
Study NCT02456584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA 300
Description: injectable contraceptive
Study NCT02456584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA 104
Description: injectable contraceptive
Study NCT01059448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: AMG 827 210 mg
Study NCT01390389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~* Visit 1 (baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above.
Study NCT00510705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise training
Description: physical exercise training on a bicycle ergometer daily for 4 weeks
Study NCT00510705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise training + metformin
Description: physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
Study NCT00510705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise training + glitazone
Description: physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
Study NCT00778830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
Study NCT00778830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
Study NCT00778830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
Study NCT00503191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NeuroModulation Technique
Description: NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
Study NCT01888094 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound-guided cannulation and examination
Study NCT01888094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation and examination
Study NCT02639377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study NCT02639377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
Study NCT02276261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal cuff closure - vertical
Description: Vaginal cuff is closed vertically.
Study NCT02276261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal cuff closure - horizontal
Description: Vaginal cuff is closed horizontally.
Study NCT03572088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
Study NCT03572088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Study NCT02511522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Including analgesics, palliative care and/or pain specialist assessment as needed
Study NCT02511522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Including analgesics, palliative care and/or pain specialist assessment as needed
Study NCT02511522 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: 8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
Study NCT06252116 — intervention group
Intervention type: DRUG
Intervention: Pregabalin group
Description: Pregabalin group
Study NCT06252116 — intervention group
Intervention type: DRUG
Intervention: Duloxetine group
Description: Duloxetine group
Study NCT01239407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally focused psychiatric consultation
Description: The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person).
Study NCT04047888 — intervention group
Intervention type: OTHER
Intervention: Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message
Description: 60 minute educational message at each visit
Study NCT00424008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) MDI
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
Study NCT00424008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol (F/SC) DPI
Description: Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
Study NCT00482092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®
Description: Prochymal® IV infusion
Study NCT03343418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
Study NCT01463917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic
Description: Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
Study NCT04047888 — intervention group
Intervention type: OTHER
Intervention: Non nutrition-based educational message
Description: No nutrition-based education on infant feeding and practices
Study NCT02947919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
Study NCT00482092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prochymal® Placebo-matching IV infusion
Study NCT06310863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers
Description: Subjects will be randomized to receive LASBEAU Strong or Restylane Lyft injections into each of the nasolabial folds on both sides.~LASBEAU Strong or Restylane Lyft Injection Box
Study NCT06310863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers
Description: Subjects will be randomized to receive LASBEAU Strong or Restylane Lyft injections into each of the nasolabial folds on both sides.~LASBEAU Strong or Restylane Lyft Injection Box
Study NCT03753906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osmed® hydrogel expander implantation
Description: Under local anaesthesia, a small vertical incision, adapted to the diameter of the Osmed® sself-inflating hydrogel expander, was made with #15 scalpel blade at the mesial line angle of the adjacent tooth which started below the gingival margin extending from the keratinized tissue above the MGJ to the non-keratinized tissue beyond the MGJ. A minimally invasive preparation of a subperiosteal pouch was performed with KPA tunnelling knife. Size of the pouch was controlled with the specific surgical template to ensure the device easily fits into the prepared pouch without tension. Expanders were secured in the correct position with a bone fixation screw, at the flat end, which does not possess an expansion capability. The wound was closed with 3-0 silk suture using simple interrupted sutures.
Study NCT02050126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis UltraPulse Encore.
Description: Treatment using Lumenis UltraPulse Encore.
Study NCT00564538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin (rabbit)
Description: 1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
Study NCT00564538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Tacrolimus will be administered orally on post op day #1 as per standard of care.
Study NCT02242591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 7,5 mg/ml
Study NCT02242591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 7,5 mg/ml
Study NCT02242591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT02242591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT01535664 — intervention group
Intervention type: OTHER
Intervention: Withdrawal of dalfampridine-ER 10mg
Description: Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)
Study NCT02858817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atovaquone/proguanil 250mg/100mg (A/P)
Description: Combination drug for chemo-prophylaxis or treatment of malaria
Study NCT02858817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atovaquone/proguanil 250mg/100mg (A/P)
Description: Combination drug for chemo-prophylaxis or treatment of malaria
Study NCT02858817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (NF54)
Description: cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
Study NCT02858817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: 0.9% NaCl solution for injection
Study NCT00911001 — intervention group
Intervention type: BEHAVIORAL
Intervention: No Drug
Description: Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
Study NCT01397097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUS (BAY 86-5028)
Description: LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
Study NCT01397097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68 mg etonorgestrel implant for subdermal use (Nexplanon)
Description: Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
Study NCT04657107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
Study NCT04657107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Saline group: pregnant women received saline, intravenous drip
Study NCT04657107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
Study NCT03757013 — intervention group
Intervention type: DRUG
Intervention: Apremilast
Description: Apremilast
Study NCT03407300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
Study NCT03407300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese traditional medicine XH1
Description: To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
Study NCT01419145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
Study NCT01419145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard cancer care
Study NCT01154023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)
Description: Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.
Study NCT03130647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound
Description: Focused ultrasound
Study NCT04184986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: dry blood test
Description: screening test for Fabry disease
Study NCT02269189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, high dose
Study NCT02269189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, low dose
Study NCT02269189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03894722 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: During the third molar extraction the saline solution will be used in the control group.
Study NCT03894722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.5% concentration of PVP-I
Description: During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
Study NCT03894722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 % concentration of PVP-I
Description: During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
Study NCT03894722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 % concentration of PVP-I
Description: During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
Study NCT00362180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 200 mg subcutaneous injections
Study NCT00362180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mipomersen
Description: 200 mg subcutaneous injections
Study NCT00362180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections
Study NCT04379492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
Study NCT04379492 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
Study NCT03821844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music and Memory
Description: Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
Study NCT02480140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-regulated constraint-induced movement therapy
Description: There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
Study NCT02480140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-induced movement therapy
Description: They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
Study NCT02480140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy
Description: They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
Study NCT02770209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biomimetic cartilage matrix + autologous chondrocytes
Study NCT02770209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic debridement
Study NCT02770209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfracture surgery
Study NCT03467009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPACT Intervention
Description: Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.